首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1378694

急性缺血性腦中風(AIS) 市場：依藥物、配銷通路、地區分類

Acute Ischemic Stroke Market, By Therapeutics, By Distribution Channel, By Geography

出版日期: 2023年10月18日 | 出版商:

Coherent Market Insights | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2023 年，全球急性缺血性腦中風(AIS) 市場規模將達到 92.1 億美元，預計在預測期內（2023-2030 年）年複合成長率為 4.0%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	92.1億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	4.00%	2030年市場規模預測	121.2億美元

圖 1. 2023 年按治療藥物分類的急性缺血性腦中風(AIS) 的全球市場佔有率(%)

當大腦動脈中的血流被血栓（一種增厚的血塊）阻塞時，就會發生急性缺血性腦中風（AIS）。根據血栓在體內形成的位置，血栓分為血栓性或栓塞。最常見的中風類型是血栓性中風，當腦動脈形成血塊時就會發生這種情況。當栓塞或小塊斑塊（脂肪沉積物）從心臟或身體其他部位脫落，進入血液並滯留在大腦的小血管中時，就會發生栓塞中風。大血管阻塞（LVO）約佔急性缺血性腦中風的一半。 LVO 是最嚴重、最使人衰弱的中風類型，因為血塊阻塞了大動脈，阻礙了血液流向大腦的重要部位。

市場動態

無機成長策略的增加，例如主要市場參與企業結盟以擴大產品系列，預計將在預測期內推動全球急性缺血性腦中風（AIS）市場的成長。例如，2021年12月，生物科技公司先聲藥業Group Limited與專注於開發神經系統疾病創新藥物的臨床階段生物科技公司Avilex Pharma（Avilex）宣布，雙方將宣佈建立戰略區域許可合作夥伴關係，共同開發和商業化靶向突觸後密度蛋白 95 (PSD-95) 的藥物可治療急性缺血性腦中風(AIS) 和其他神經系統疾病。該協議授予先聲藥業Group Limited獨家區域許可，以開發和商業化 Avilex 的 2-ready 二聚體 PSD-95 抑制劑 AVLX-144，用於治療 AIS 和其他神經系統疾病。 AVLX-144 是一種胜肽樣候選藥物，用於治療 AIS，其靶向細胞內支架蛋白 PSD-95。 AVLX-144 是一種廣泛最佳化的二聚體 PSD-95 抑制劑，也是治療 AIS 和蛛網膜下腔出血 (SAH) 等急性疾病的臨床主要候選藥物。

本研究的主要特點

本報告對全球急性缺血性腦中風（AIS）市場進行了詳細分析，並列出了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率。
它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
本報告根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球急性缺血性腦中風(AIS) 市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
全球急性缺血性腦中風(AIS) 市場迎合該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球急性缺血性腦中風（AIS）市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson &Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck &Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

第9章章節

參考
調查方法

簡介目錄

Product Code: CMI4483

Global acute ischemic stroke (AIS) market is estimated to be valued at US$ 9.21 Bn in 2023, and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 9.21 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	4.00%	2030 Value Projection:	US$ 12.12 Bn

Figure 1. Global Acute Ischemic Stroke (AIS) Market Share (%), By Therapeutics, 2023

Acute ischemic stroke (AIS) occurs when blood flow through a brain artery is obstructed by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where these form in the body. The most common type of stroke is a thrombotic stroke thatoccurs when a clot forms within a brain artery. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body such as the heart, and travels through the bloodstream before becoming lodged in a narrower vessel in the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. LVO is the most serious and debilitating type of stroke because the clot blocks large arteries, and prevents blood flow to essential parts of the brain.

Market Dynamics

Increasing inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio is expected to drive the global acute ischemic stroke (AIS) market growth over the forecast period. For instance, in December 2021, Simcere Pharmaceutical Group Ltd, a biotechnology company, and Avilex Pharma (Avilex), a clinical-stage biotechnology company that focuses on developing innovative medicines for neurological disorders, announced a strategic regional licensing partnership to develop and commercialize medicines that target the postsynaptic density protein 95 (PSD-95) to treat acute ischemic stroke (AIS) and other neurological conditions in greater China. The agreement granted Simcere Pharmaceutical Group Ltd an exclusive regional license to develop and commercialize AVLX-144, Avilex's 2-ready dimeric PSD-95 inhibitor, for the treatment of AIS and other neurological conditions. AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS that targets the intracellular scaffolding protein- PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH).

Key features of the study:

This report provides an in-depth analysis of the global acute ischemic stroke (AIS) market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global acute ischemic stroke (AIS) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include F.Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bayer AG, Pfizer Inc., Biogen, DAIICHI SANKYO COMPANY, LIMITED, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, SanBio Co,Ltd., Athersys, Inc., Abbott, Sanofi, ZZ Biotech, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., NoNO Inc., AliveCor, Inc., Amgen Inc., Genentech USA, Inc., and DiaMedica Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global acute ischemic stroke (AIS) market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute ischemic stroke (AIS) market

Acute Ischemic Stroke (AIS) Market Detailed Segmentation:

By Therapeutics:
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapeutics
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Opportunities
- Impact Analysis
- Recent Trends
- Product Launches and Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis

4. Global Acute Ischemic Stroke (AIS) Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Acute Ischemic Stroke (AIS) Market, By Therapeutics, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Tissue Plasminogen Activator
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Anticoagulant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Antiplatelet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Antihypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

6. Global Acute Ischemic Stroke (AIS) Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

7. Global Acute Ischemic Stroke (AIS) Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Boehringer Ingelheim International GmbH
- Bayer AG
- Pfizer Inc.
- Biogen
- DAIICHI SANKYO COMPANY, LIMITED
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- AstraZeneca
- SanBio Co,Ltd.
- Athersys, Inc.
- Abbott
- Sanofi
- ZZ Biotech
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- NoNO Inc.
- AliveCor, Inc.
- Amgen Inc.
- Genentech USA, Inc.
- DiaMedica Therapeutics, Inc.

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

急性缺血性腦中風治療藥的全球市場 2023-2027

FAQ

急性缺血性腦中風(AIS) 市場：依藥物、配銷通路、地區分類